Pharmaceuticals: Sanofi and Shire mentioned as potential suitors for ViroPharma
The press reports that ViroPharma is attracting interest from suitors including the two European companies Sanofi and Shire and, as a consequence, it has began working with Goldman Sachs to prepare its defence. The company had a market value of around USD2bn before rumours started. It is a specialist in rare diseases with the flagship product Cinryze, a treatment for hereditary angioedema (HAE) whose sales are expected to reach USD400m this year. It makes sense for both companies but Shire has undoubtedly more synergies than others to benefit from such a move.
Full report available to subscribers
Please contact firstname.lastname@example.org